Angiotensin II type 2 receptor-interacting protein prevents vascular senescence.

Li-Juan Min,Masaki Mogi,Jun Iwanami,Fei Jing,Kana Tsukuda,Kousei Ohshima,Masatsugu Horiuchi
DOI: https://doi.org/10.1016/j.jash.2012.01.006
2012-01-01
Journal of the American Society of Hypertension
Abstract:Angiotensin II type 2 (AT2) receptor-interacting protein (ATIP), which interacts with the C-terminal tail of the AT2 receptor, regulates the functions of the AT2 receptor. We have reported that AT2 receptor stimulation attenuated vascular senescence. Therefore, we examined the possible negative role of ATIP in regulating vascular senescence. We generated ATIP-transgenic (Tg) mice, and cultured vascular smooth muscle cells (VSMCs). Persistent angiotensin II stimulation induced increases in SA-β-gal–positive cells and the level of a DNA damage marker, 8-OHdG in VSMC, whereas these effects of angiotensin II were attenuated in VSMC prepared from ATIP-Tg mice. Angiotensin II treatment also upregulated the expression of methyl methanesulfonate-sensitive 2 (MMS2), a DNA repair factor, and Src homology 2 domain-containing protein-tyrosine phosphatase 1 (SHP-1) activity, whereas these effects of angiotensin II were further enhanced in ATIP-Tg VSMC. In vivo, x-ray irradiation to mice caused increases in SA-β-gal–positive area and 8-OHdG level in the thoracic aorta; however, these effects were reduced in ATIP-Tg mice, with a significant increase in MMS2 expression. These results suggest that ATIP could inhibit VSMC senescence, involving MMS2 expression and SHP-1 activity. ATIP might be a new therapeutic molecule to treat vascular aging and age-related vascular diseases.
What problem does this paper attempt to address?